Visceral Pain Treatment Market Is Expanding Rapidly With Takeda Pharmaceutical Company Announcing Results For The Safety And Efficacy Of Subcutaneous Entyvio Indicated For The Treatment Of Moderately To Severely Active Ulcerative Colitis
Visceral pain can be a difficult condition to deal with especially if it affects the abdominal region. Although it is very common, only a small percentage of people who are diagnosed with this condition actually experience severe symptoms. Visceral pain is characterized by an intense pain that originates in the abdomen and radiates from the lower back down the hip area and into the legs. Although some people may only feel mild or moderate discomfort from it, for many this will be a chronic problem that can result in pain permanently. Government and pharmaceutical organizations are focused on continuous research and development activities, in order to come up with an innovative approach for visceral pain treatment. Many pharmaceutical companies are involved in collaborative agreements and research to expand their R&D activities. Recently, in February 2020, Novartis collaborated with the Drugs for Neglected Diseases initiative (DNDi) to develop LXE408, a new oral drug for...